OSR (OSRH) versus The Competition Head-To-Head Survey

OSR (NASDAQ:OSRH) is one of 844 publicly-traded companies in the “Biotechnology” industry, but how does it compare to its peers? We will compare OSR to related businesses based on the strength of its dividends, analyst recommendations, profitability, earnings, institutional ownership, risk and valuation.

Profitability

This table compares OSR and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
OSR	-593.15%	-8.36%	-6.24%
OSR Competitors	-12,285.98%	-196.04%	-30.61%

Institutional & Insider Ownership

55.3% of OSR shares are held by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are held by institutional investors. 36.9% of OSR shares are held by insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares OSR and its peers top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
OSR	$1.81 million	-$27.06 million	-0.38
OSR Competitors	$714.22 million	$11.22 million	-15.14

OSR’s peers have higher revenue and earnings than OSR. OSR is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Analyst Recommendations

This is a summary of current ratings and target prices for OSR and its peers, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OSR	1	0	0	0	1.00
OSR Competitors	9858	15137	45528	1590	2.54

As a group, “Biotechnology” companies have a potential upside of 99.18%. Given OSR’s peers stronger consensus rating and higher possible upside, analysts clearly believe OSR has less favorable growth aspects than its peers.

Risk and Volatility

OSR has a beta of 0.65, indicating that its stock price is 35% less volatile than the S&P 500. Comparatively, OSR’s peers have a beta of 1.15, indicating that their average stock price is 15% more volatile than the S&P 500.

Summary

OSR peers beat OSR on 7 of the 13 factors compared.

About OSR

OSR Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D “platform technologies” versus “assets only” companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials.